Opinion: Our next vaccine must stomp out variants to end COVID pandemics once and for all

Steve A. N. Goldstein, MA, MD, Ph.D., FAAP, vice chancellor of Health Affairs at the University of California, Irvine writes, “At the University of California, Irvine, our pan-coronavirus program that is designed to protect against COVID-19, the common cold and coronaviruses … has already entered phase 1 clinical trials. As we await the trial results, it is incumbent on national and international governing bodies, the pharmaceutical, health and nonprofit sectors and the social enterprise community to innovate so we can manufacture, supply and deploy the vaccine around the globe.”